Found 1 Presentation For Request "1339P"
1339P - Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB)
- Shivani Aggarwal (Thousand Oaks, CA, United States of America)
We performed a retrospective study of adult advanced NSCLC patients who were treated in the Flatiron Health network between January 2011–March 2019 with a
743 advanced NSCLC
This is the largest observational study characterizing NSCLC patients with
Legal entity responsible for the study
S. Aggarwal, S. Whipple, H. Tu, G. Carrigan, X. Wang, G. Ngarmchamnanrith, V. Chia: Shareholder/Stockholder/Stock options, Full/Part-time employment: Amgen. H. Hsu: Shareholder/Stockholder/Stock options, Full/Part-time employment: Amgen; Full/Part-time employment, Left in July 2019: Skye Biologics, Inc.